CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 20 enrolled
Drug / intervention
Lucinactantdrug
Likely dose
Lucinactant 80 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04389671
NCT04389671Phase 2Completed
CompareCT.gov

A Multicenter, Single-Treatment Study to Assess the Safety and Tolerability of Lyophilized Lucinactant in Adults With COVID-19 Associated Acute Lung Injury

Windtree Therapeutics·interventional·Posted May 15, 2020·Updated Jun 23, 2023

In Brief

A Phase 2 clinical trial evaluating Lucinactant for COVID-19 and Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS). Completed, enrolled 20 participants across 11 sites in 2 countries.

Detailed Summary

This is a multicenter, single-treatment study. Subjects will consist of adults with COVID-19 associated acute lung injury who are being cared for in a critical care environment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19, Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)
CountriesArgentina, United States
Collaborators--

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedMay 15, 2020
Enrollment StartJan 5, 2021
Primary CompletionFeb 20, 2022
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 6.1 years ago

Interventions

Lucinactantdrug

Lucinactant administered as a liquid at a dose of 80 mg total phospholipids (TPL)/kg lean body weight delivered